DE1212679B
(de)
|
1957-08-03 |
1966-03-17 |
Novo Terapeutisk Labor As |
Verfahren zur Herstellung von Insulinloesungen
|
GB1042194A
(en)
|
1962-04-30 |
1966-09-14 |
Olin Mathieson |
Insulin preparations
|
US3528960A
(en)
|
1968-10-07 |
1970-09-15 |
Lilly Co Eli |
N-carboxyaroyl insulins
|
US3907676A
(en)
|
1970-07-28 |
1975-09-23 |
Novo Terapeutisk Labor As |
Process for purifying insulin
|
US3868358A
(en)
|
1971-04-30 |
1975-02-25 |
Lilly Co Eli |
Protamine-insulin product
|
GB1492997A
(en)
|
1976-07-21 |
1977-11-23 |
Nat Res Dev |
Insulin derivatives
|
JPS5767548A
(en)
|
1980-10-14 |
1982-04-24 |
Shionogi & Co Ltd |
Insulin analog and its preparation
|
FI78616C
(fi)
|
1982-02-05 |
1989-09-11 |
Novo Industri As |
Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
|
US4876322A
(en)
|
1984-08-10 |
1989-10-24 |
Siemens Aktiengesselschaft |
Irradiation cross-linkable thermostable polymer system, for microelectronic applications
|
EP0174493B1
(de)
|
1984-08-17 |
1988-05-25 |
Bayer Ag |
Thermoplastische Formmassen mit flammwidrigen Eigenschaften
|
DE3433367A1
(de)
|
1984-09-12 |
1986-03-20 |
Robert Bosch Gmbh, 7000 Stuttgart |
Einrichtung zur steuerung der energiezufuhr zu einer heissen stelle
|
PH25772A
(en)
|
1985-08-30 |
1991-10-18 |
Novo Industri As |
Insulin analogues, process for their preparation
|
US5605884A
(en)
|
1987-10-29 |
1997-02-25 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Factor VIII formulations in high ionic strength media
|
US4877608A
(en)
|
1987-11-09 |
1989-10-31 |
Rorer Pharmaceutical Corporation |
Pharmaceutical plasma protein formulations in low ionic strength media
|
DE3827533A1
(de)
|
1988-08-13 |
1990-02-15 |
Hoechst Ag |
Pharmazeutische zubereitung zur behandlung des diabetes mellitus
|
HUT56857A
(en)
|
1988-12-23 |
1991-10-28 |
Novo Nordisk As |
Human insulin analogues
|
IL93282A
(en)
|
1989-02-09 |
1995-08-31 |
Lilly Co Eli |
Insulin analogues
|
IT1240314B
(it)
|
1989-09-28 |
1993-12-07 |
Immunobiology Research Institutes, Inc. |
Formulazioni acquose stabilizzate di piccoli peptidi.
|
CA2070814A1
(en)
|
1989-12-21 |
1991-06-22 |
Klavs H. Jorgensen |
Insulin preparations containing nicotinic acid or nicotinamide
|
DK45590D0
(da)
|
1990-02-21 |
1990-02-21 |
Novo Nordisk As |
|
DK175491D0
(da)
|
1991-10-18 |
1991-10-18 |
Novo Nordisk As |
Apparat
|
ES2185625T3
(es)
|
1991-12-20 |
2003-05-01 |
Novo Nordisk As |
Formulacion farmaceutica estabilizada que incluye hormona de crecimiento e histidina.
|
US5672581A
(en)
|
1993-01-29 |
1997-09-30 |
Aradigm Corporation |
Method of administration of insulin
|
US6011007A
(en)
|
1993-09-17 |
2000-01-04 |
Novo Nordisk A/S |
Acylated insulin
|
US6869930B1
(en)
|
1993-09-17 |
2005-03-22 |
Novo Nordisk A/S |
Acylated insulin
|
BR9407508A
(pt)
|
1993-09-17 |
1997-01-07 |
Novo Nordisk As |
Derivado de insulina composição farmaceutica e processo para o tratamento de diabete em um paciente com necessidade deste tratamento
|
US5652216A
(en)
|
1994-05-26 |
1997-07-29 |
Novo Nordisk A/S |
Pharmaceutical preparation
|
AU3562195A
(en)
|
1994-10-04 |
1996-04-26 |
Novo Nordisk A/S |
Preparations containing aspb28 human insulin and nicotinamide
|
US5646242A
(en)
|
1994-11-17 |
1997-07-08 |
Eli Lilly And Company |
Selective acylation of epsilon-amino groups
|
US5693609A
(en)
|
1994-11-17 |
1997-12-02 |
Eli Lilly And Company |
Acylated insulin analogs
|
US5830999A
(en)
|
1995-01-26 |
1998-11-03 |
Regents Of The University Of California |
Stabilization of insulin through ligand binding interations
|
DE69629210T2
(de)
|
1995-03-17 |
2004-04-22 |
Novo Nordisk A/S |
Insulinabkömmlinge
|
US6251856B1
(en)
|
1995-03-17 |
2001-06-26 |
Novo Nordisk A/S |
Insulin derivatives
|
CN100360184C
(zh)
|
1995-07-27 |
2008-01-09 |
基因技术股份有限公司 |
稳定等渗的冻干蛋白质制剂
|
US6451970B1
(en)
|
1996-02-21 |
2002-09-17 |
Novo Nordisk A/S |
Peptide derivatives
|
US5866538A
(en)
|
1996-06-20 |
1999-02-02 |
Novo Nordisk A/S |
Insulin preparations containing NaCl
|
DE69731105T2
(de)
|
1996-07-11 |
2005-11-17 |
Novo Nordisk A/S |
Verfahren zur selektiven acetylierung
|
US5905140A
(en)
|
1996-07-11 |
1999-05-18 |
Novo Nordisk A/S, Novo Alle |
Selective acylation method
|
US5763401A
(en)
|
1996-07-12 |
1998-06-09 |
Bayer Corporation |
Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
|
DK0821006T3
(da)
|
1996-07-26 |
2004-08-16 |
Aventis Pharma Gmbh |
Insulinderivater med öget zinkbinding
|
IL119029A0
(en)
|
1996-08-07 |
1996-11-14 |
Yeda Res & Dev |
Long-acting drugs and pharamaceutical compositions comprising them
|
US5898067A
(en)
|
1997-02-07 |
1999-04-27 |
Novo Nordisk A/S |
Crystallization of proteins
|
AU6611898A
(en)
|
1997-03-20 |
1998-10-20 |
Novo Nordisk A/S |
Method for preparation of a therapeutic powder through coprecipitation of insulin and absorption enhancer
|
EP0971729B1
(en)
|
1997-03-20 |
2002-07-03 |
Novo Nordisk A/S |
Therapeutic powder formulation for pulmonary administration, containing crystalline insulin
|
US7097845B2
(en)
|
1997-04-23 |
2006-08-29 |
Jacob Sten Petersen |
Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
|
EP1283051B1
(en)
|
1997-06-13 |
2006-06-14 |
Eli Lilly And Company |
Stable insulin formulations
|
PE79099A1
(es)
|
1997-06-13 |
1999-08-24 |
Lilly Co Eli |
Formulaciones de insulina estables
|
WO1999021573A1
(en)
|
1997-10-24 |
1999-05-06 |
Eli Lilly And Company |
Fatty acid-acylated insulin analogs
|
US20020155994A1
(en)
|
1997-10-24 |
2002-10-24 |
Svend Havelund |
Aggregates of human insulin derivatives
|
US6451762B1
(en)
|
1997-10-24 |
2002-09-17 |
Novo Nordisk A/S |
Aggregates of human insulin derivatives
|
HUP0004096A3
(en)
|
1997-10-24 |
2001-12-28 |
Novo Nordisk As |
Aggregates of human insulin derivatives and pharmaceutical compositions comprising thereof
|
ZA989744B
(en)
|
1997-10-31 |
2000-04-26 |
Lilly Co Eli |
Method for administering acylated insulin.
|
ES2230727T3
(es)
|
1997-11-12 |
2005-05-01 |
Alza Corporation |
Procedimiento de administracion dermal de polipeptidos.
|
CO4970787A1
(es)
|
1997-12-23 |
2000-11-07 |
Lilly Co Eli |
Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
|
AU1870099A
(en)
|
1998-01-09 |
1999-07-26 |
Novo Nordisk A/S |
Stabilised insulin compositions
|
ATE277630T1
(de)
|
1998-10-16 |
2004-10-15 |
Novo Nordisk As |
Stabile konzentrierte insulin präparationen zur pulmonaren verabreichung
|
US6211144B1
(en)
|
1998-10-16 |
2001-04-03 |
Novo Nordisk A/S |
Stable concentrated insulin preparations for pulmonary delivery
|
PT1146896E
(pt)
|
1999-01-26 |
2002-10-31 |
Lilly Co Eli |
Formulacoes monodispersas de analogo acilado e hexamerico insulina
|
PL204701B1
(pl)
|
1999-02-22 |
2010-02-26 |
Baxter Int |
Liofilizowana kompozycja czynnika VIII bez dodatku albuminy i jej zastosowanie
|
AU4450700A
(en)
|
1999-04-27 |
2000-11-10 |
Eli Lilly And Company |
Insulin crystals for pulmonary administration
|
GB9930882D0
(en)
|
1999-12-30 |
2000-02-23 |
Nps Allelix Corp |
GLP-2 formulations
|
DE10022092A1
(de)
|
2000-05-08 |
2001-11-15 |
Aventis Behring Gmbh |
Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
|
US6652886B2
(en)
|
2001-02-16 |
2003-11-25 |
Expression Genetics |
Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
|
DE10114178A1
(de)
|
2001-03-23 |
2002-10-10 |
Aventis Pharma Gmbh |
Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
|
AU2002316811A1
(en)
|
2001-06-28 |
2003-03-03 |
Novo Nordisk A/S |
Stable formulation of modified glp-1
|
JP2004537580A
(ja)
|
2001-08-10 |
2004-12-16 |
エピックス メディカル, インコーポレイテッド |
延長された循環半減期を有するポリペプチド結合体
|
US20030068361A1
(en)
|
2001-10-09 |
2003-04-10 |
Rimona Margalit |
Liposome-encapsulated insulin formulations
|
AU2002346490A1
(en)
|
2001-12-20 |
2003-07-09 |
Eli Lilly And Company |
Insulin molecule having protracted time action
|
WO2003075950A1
(en)
|
2002-03-13 |
2003-09-18 |
Novo Nordisk A/S |
Minimising body weight gain in insulin treatment
|
ATE496064T1
(de)
|
2002-05-07 |
2011-02-15 |
Novo Nordisk As |
Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
|
JP2005526126A
(ja)
|
2002-05-07 |
2005-09-02 |
ノボ ノルディスク アクティーゼルスカブ |
インスリンアスパルト及びインスリンデテミアを含む可溶性製剤
|
US20050232899A1
(en)
|
2002-05-31 |
2005-10-20 |
Aradigm Corporation |
Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
|
US20040002451A1
(en)
|
2002-06-20 |
2004-01-01 |
Bruce Kerwin |
Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
|
KR100615389B1
(ko)
|
2002-08-23 |
2006-08-25 |
(주)헬릭서 |
다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품
|
JP2006504772A
(ja)
|
2002-10-29 |
2006-02-09 |
アルザ・コーポレーション |
安定化された固体ポリペプチド粒子
|
US20040138099A1
(en)
|
2002-11-29 |
2004-07-15 |
Draeger Eberhard Kurt |
Insulin administration regimens for the treatment of subjects with diabetes
|
BRPI0407303A
(pt)
|
2003-02-07 |
2006-02-07 |
Ajinomoto Kk |
Composição farmacêutica
|
DE602004027992D1
(de)
|
2003-02-19 |
2010-08-19 |
Novartis Ag |
In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135
|
ATE485051T1
(de)
|
2003-03-04 |
2010-11-15 |
Technology Dev Company Ltd |
Injizierbare insulinzubereitung mit langzeitwirkung und verfahren zur dessen herstellung und verwendung
|
WO2004112828A1
(en)
|
2003-06-25 |
2004-12-29 |
Novo Nordisk Health Care Ag |
Liquid composition of factor vii polypeptides
|
US20050054818A1
(en)
|
2003-07-02 |
2005-03-10 |
Brader Mark Laurence |
Crystalline compositions for controlling blood glucose
|
EP1644411A2
(en)
|
2003-07-11 |
2006-04-12 |
Novo Nordisk A/S |
Stabilised insulin compositions
|
EP1660531A2
(en)
|
2003-08-05 |
2006-05-31 |
Novo Nordisk A/S |
Novel insulin derivatives
|
EP2287184A3
(en)
|
2003-08-05 |
2011-08-10 |
Novo Nordisk A/S |
Novel insulin derivatives
|
CA2534028A1
(en)
|
2003-08-14 |
2005-02-24 |
Novo Nordisk Health Care Ag |
Liquid, aqueous pharmaceutical composition of factor vii polypeptides
|
WO2005021022A2
(en)
|
2003-09-01 |
2005-03-10 |
Novo Nordisk A/S |
Stable formulations of peptides
|
ES2229931B1
(es)
|
2003-10-03 |
2006-01-16 |
Grifols, S.A. |
Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
|
JP2007532096A
(ja)
|
2003-11-14 |
2007-11-15 |
ノボ ノルディスク アクティーゼルスカブ |
アシル化されたインスリンの製造方法
|
WO2005063298A1
(en)
|
2003-12-23 |
2005-07-14 |
Pharmacia Corporation |
Stable growth hormone liquid formulation
|
EP1740154B1
(en)
|
2004-03-12 |
2009-06-17 |
Biodel, Inc. |
Insulin compositions with improved absorption
|
EA012281B1
(ru)
|
2004-06-01 |
2009-08-28 |
Арес Трейдинг С.А. |
Способ стабилизации белков
|
WO2006008238A1
(en)
|
2004-07-16 |
2006-01-26 |
Novo Nordisk A/S |
Method for selective acylation
|
AU2005272862B2
(en)
|
2004-08-12 |
2011-03-10 |
Merck Sharp & Dohme Corp. |
Stable pegylated interferon formulation
|
EP2311871A3
(en)
|
2004-08-17 |
2012-08-08 |
Regeneron Pharmaceuticals, Inc. |
IL-1 antagonist stable liquid formulation
|
ES2575984T3
(es)
|
2004-11-12 |
2016-07-04 |
Novo Nordisk A/S |
Formulaciones estables de péptidos que contienen un análogo de GLP-1 acilado y una insulina basal
|
WO2006053906A1
(en)
|
2004-11-22 |
2006-05-26 |
Novo Nordisk A/S |
Soluble, stable insulin-containing formulations with a protamine salt
|
WO2006079019A2
(en)
|
2005-01-21 |
2006-07-27 |
Alza Corporation |
Therapeutic peptide formulations for coating microneedles with improved stabitity containing at least one counterion
|
ES2435522T3
(es)
|
2005-02-02 |
2013-12-20 |
Novo Nordisk A/S |
Derivados de insulina
|
JP4933455B2
(ja)
|
2005-02-02 |
2012-05-16 |
ノヴォ ノルディスク アー/エス |
新規のインスリン誘導体
|
WO2007041481A1
(en)
|
2005-09-29 |
2007-04-12 |
Biodel, Inc. |
Rapid acting and prolonged acting insulin preparations
|
EP1951198B1
(en)
|
2005-10-20 |
2010-06-16 |
MDRNA, Inc. |
Intranasal administration of rapid acting insulin
|
CN101389650B
(zh)
|
2005-12-28 |
2012-10-10 |
诺沃-诺迪斯克有限公司 |
包含酰化胰岛素和锌的组合物以及制备所述组合物的方法
|
ES2387955T3
(es)
|
2006-02-27 |
2012-10-04 |
Novo Nordisk A/S |
Derivados de insulina
|
CN101454019A
(zh)
|
2006-04-12 |
2009-06-10 |
百达尔公司 |
速效和长效胰岛素联合制剂
|
EP2012817A2
(en)
|
2006-04-12 |
2009-01-14 |
Biodel, Inc. |
Rapid acting and long acting insulin combination formulations
|
US8796205B2
(en)
|
2006-05-09 |
2014-08-05 |
Novo Nordisk A/S |
Insulin derivative
|
ES2548393T3
(es)
|
2006-05-09 |
2015-10-16 |
Novo Nordisk A/S |
Derivado de insulina
|
WO2007135117A2
(en)
|
2006-05-24 |
2007-11-29 |
Novo Nordisk A/S |
Soluble, stable insulin-containing formulations
|
EP2074141B1
(en)
|
2006-09-22 |
2016-08-10 |
Novo Nordisk A/S |
Protease resistant insulin analogues
|
CN101677947B
(zh)
|
2007-06-13 |
2013-07-17 |
诺沃-诺迪斯克有限公司 |
包含胰岛素衍生物的药物制剂
|
ES2526924T3
(es)
|
2007-08-15 |
2015-01-16 |
Novo Nordisk A/S |
Insulinas con una fracción acilo que comprende unidades repetitivas de aminoácidos que contienen alquilenglicol
|
EP2036539A1
(en)
|
2007-09-11 |
2009-03-18 |
Novo Nordisk A/S |
Stable formulations of amylin and its analogues
|
CN101932601B
(zh)
|
2007-11-08 |
2016-08-03 |
诺沃-诺迪斯克有限公司 |
胰岛素衍生物
|
WO2009063072A2
(en)
|
2007-11-16 |
2009-05-22 |
Novo Nordisk A/S |
Pharmaceutical compositions containing insulin and an insulinotropic peptide
|
DK2910570T3
(da)
|
2008-03-18 |
2017-01-30 |
Novo Nordisk As |
Protease-stabiliserede, acylerede insulinanaloger.
|
TWI451876B
(zh)
|
2008-06-13 |
2014-09-11 |
Lilly Co Eli |
聚乙二醇化之離脯胰島素化合物
|
EP2352513B1
(en)
*
|
2008-10-30 |
2016-09-14 |
Novo Nordisk A/S |
Treating diabetes melitus using insulin injections with less than daily injection frequency
|
US20130143803A1
(en)
|
2010-05-10 |
2013-06-06 |
Novo Nordisk A/S |
Process for the Preparation of Insulin-Zinc Complexes
|
AU2011202239C1
(en)
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
EP2389945A1
(en)
|
2010-05-28 |
2011-11-30 |
Sanofi-Aventis Deutschland GmbH |
Pharmaceutical composition comprising AVE0010 and insulin glargine
|
DK2632478T3
(da)
|
2010-10-27 |
2019-10-07 |
Novo Nordisk As |
Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
|
PL2632478T3
(pl)
|
2010-10-27 |
2020-03-31 |
Novo Nordisk A/S |
Leczenie cukrzycy z zastosowaniem zastrzyków insuliny podawanych w różnych odstępach czasu
|
KR20140007377A
(ko)
|
2011-02-01 |
2014-01-17 |
노보 노르디스크 에이/에스 |
인슐린의 정제
|
EP4070801A1
(en)
|
2011-03-01 |
2022-10-12 |
Nutrition 21, LLC |
Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
|
CN103813821B
(zh)
|
2011-09-13 |
2017-06-13 |
诺沃—诺迪斯克有限公司 |
用于随时间优化药物剂量方案的自适应系统
|
ES2594303T3
(es)
|
2012-04-11 |
2016-12-19 |
Novo Nordisk A/S |
Formulaciones de insulina
|
JP6262206B2
(ja)
|
2012-05-01 |
2018-01-17 |
ノヴォ ノルディスク アー/エス |
医薬組成物
|
EP2976096B1
(en)
|
2013-03-20 |
2019-02-27 |
Novo Nordisk A/S |
Insulin dosing regimen
|
US9839579B2
(en)
|
2013-04-24 |
2017-12-12 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
WO2014177623A1
(en)
|
2013-04-30 |
2014-11-06 |
Novo Nordisk A/S |
Novel administration regime
|